US FDA approves J&J's immune disorder drug

(Reuters) -The U.S. Food and Drug Administration has approved Johnson & Johnson's drug to treat some patients aged 12 years and older with an immune-mediated disorder, the drugmaker said on Wednesday. The drug, which will be sold under the brand name Imaavy, was approved for patients with generalized myasthenia gravis - an immunity-related disorder that weakens the skeletal muscles, especially